BMJ open · 2026
Multimodality detection of early relapse in radically treated high-risk HPV-negative head and neck squamous cell carcinoma: study protocol for a prospective multicentre UK cohort study (HERD).
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mithra Sanjena, Ahmed Ahmed Abdullah, Roshan Amit, Barber Paul R, de Carvalho Gomes Camila, Coolen Ton, Sawyer Elinor, Rosenfeld Nitzan, Sinkus Ralph, Reis-Ferreira Miguel, Connor Steve, Shmueli Karin, Morley Simon, Nenclares Pablo, Apsey Caroline, Hackshaw Allan, Arora Asit, Beeston Teresita, Tuazon Juel, Berin Michelle, Yeung Antonia, Curtis Chris, Ng Kenrick, Mustapha Rami, Gillett Cheryl, Issa Balqiisa, Brew-Graves Chris, Lioumi Maria, Ng Tony, Forster Martin
Аннотация
INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer globally, with over 12 000 new cases annually in the UK. Despite aggressive radical treatment, approximately 50% of patients with locally advanced (stage III/IV), human papilloma virus (HPV)-negative disease relapse within 2 years, often in the first year. Although current post-treatment follow-up schedules are recommended by clinical guidelines, imaging surveillance is led by symptoms after the initial 3 months and reliable biomarkers for early relapse are lacking. Consequently, recurrences are frequently detected too late for surgical salvage, though timely surgery can improve survival by up to 73% in selected cases. Head and Neck Early Relapse Detection Study represents a large-scale, prospective effort to integrate imaging, genomic, immunologic and microbiome datasets for relapse risk stratification and post-treatment surveillance in this high-risk patient group.
METHODS AND ANALYSIS: Design: Prospective, observational cohort study.
SETTING: Secondary and tertiary NHS hospitals in the UK.
PARTICIPANTS: Recruiting up to 200 patients with stage III/IV (high-risk) HPV-negative HNSCC. Participants are enrolled into discovery (n=100) and validation (n=100) cohorts. Patients with HPV-positive tumours, metastatic disease or other contraindications defined in the protocol will be excluded.
INTERVENTIONS: Observational study with no experimental intervention. Participants are followed for 2 years with longitudinal collection of blood, saliva, urine, stool, fresh and archival tumour tissue and advanced MRI where possible in addition to their standard of clinical care.
PRIMARY OUTCOMES: Development and independent validation of a multimodal recurrence risk prediction model.
SECONDARY OUTCOMES: Identifying patient populations for primary treatment stratification, establishment of a longitudinal biorepository and identifying biological mechanisms of recurrence. Multimodal data will be integrated using machine learning and Bayesian modelling.
ETHICS AND DISSEMINATION: Ethical approval was granted by the Bromley Research Ethics Committee (21/PR/1581). Findings will be disseminated through peer-reviewed publications, conference presentations and scientific meetings.
TRIAL REGISTRATION NUMBER: NCT05097625.
METHODS AND ANALYSIS: Design: Prospective, observational cohort study.
SETTING: Secondary and tertiary NHS hospitals in the UK.
PARTICIPANTS: Recruiting up to 200 patients with stage III/IV (high-risk) HPV-negative HNSCC. Participants are enrolled into discovery (n=100) and validation (n=100) cohorts. Patients with HPV-positive tumours, metastatic disease or other contraindications defined in the protocol will be excluded.
INTERVENTIONS: Observational study with no experimental intervention. Participants are followed for 2 years with longitudinal collection of blood, saliva, urine, stool, fresh and archival tumour tissue and advanced MRI where possible in addition to their standard of clinical care.
PRIMARY OUTCOMES: Development and independent validation of a multimodal recurrence risk prediction model.
SECONDARY OUTCOMES: Identifying patient populations for primary treatment stratification, establishment of a longitudinal biorepository and identifying biological mechanisms of recurrence. Multimodal data will be integrated using machine learning and Bayesian modelling.
ETHICS AND DISSEMINATION: Ethical approval was granted by the Bromley Research Ethics Committee (21/PR/1581). Findings will be disseminated through peer-reviewed publications, conference presentations and scientific meetings.
TRIAL REGISTRATION NUMBER: NCT05097625.